(TheNewswire)
Toronto, Ontario / TheNewswire / March 26, 2018 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce its
participation in a Natural Sciences and Engineering Research Council (NSERC) Eng age
grant for the development of automatic detection of all four chambers of the heart in echocardiographic views using artificial
intelligence (AI), which will reduce time spent on analysis and training costs, and improve accuracy and comparability.
The NSERC funding has enabled us to partner with a top researcher at Ryerson University’s Department of
Computer Science, Dr. Konstantinos Derpanis, on a project to further advance the Al capabilities that are already imbedded in our
VMS+™ products. “This is very exciting for Ventripoint and the healthcare community at large because it allows us to bring new
technology to market that will ultimately improve clinical outcomes and reduce overall cost of care,” said Desmond Hirson,
President of Ventripoint.
The further development of such technologies is consistent with Ventripoint’s corporate mission of being a
leader in providing medical products that use AI to enhance the productivity, accuracy and consistency of cardiac measurements. The
benefits of this technology can also be extended to other modalities and imaging technologies, such as MRI and CT, to further
expand the use of AI in the field of Medical Imaging.
About Ryerson
Ryerson University is Canada’s leader in innovative, career-oriented education. Urban, culturally diverse
and inclusive, the university is home to more than 43,000 students, including 2,600 Masters and PhD students, 3,100 faculty and
staff, and nearly 185,000 alumni worldwide. For more information, visit www.ryerson.ca
About NSERC
NSERC invests over $1.2 billion each year in natural sciences and engineering research in Canada. Its
investments deliver discoveries – valuable world-firsts in knowledge claimed by a brain trust of over 11,000 professors.
Investments enable partnerships and collaborations that connect industry with discoveries and the people behind them.
Researcher-industry partnerships established by NSERC help inform research and development and solve scale-up
challenges.
NSERC also provides scholarships and hands-on training experience for more than 30,000
post-secondary students and post-doctoral fellows. These young researchers will be the next generation of science and engineering
leaders in Canada.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based
Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the
first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has
developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac
care.
For further information, please contact:
Dr. George Adams, CEO
Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing",
"may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking
information or statements. The forward-looking statements and information are based on certain key expectations and assumptions
made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and
information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking
statements and information address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other
factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most
recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news
release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news
release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any
forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required
by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.